Edgewise Therapeutics offers approximately 14% upside to the near-term price target with a roughly 2-to-1 favorable risk/reward ratio, and analyst consensus implies approximately 31% upside; however, quality metrics — reflecting cash-burning operations and a pipeline concentrated in just two clinical programs — fall well below the minimum threshold required for a position, making the setup a watch-and-validate rather than an actionable entry.
Thesis pillars
- Analyst Consensus Upside Optionality↓Deteriorating
- High Short Interest Bearish Signal↓Deteriorating
- Two Asset Pipeline Binary Risk↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 26, 2026· older than 90 days
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $37.68: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 3.45; Below-average business quality.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for rare muscle diseases, with sevasemten in a pivotal cohort for Becker muscular dystrophy and multiple Phase 2 trials for Duchenne, plus EDG-7500 in Phase 2 for... Read more
Sell if holding. Engine safety override at $37.68: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 3.45; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.2/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 0d<=7d. Suitability: speculative.
About Edgewise Therapeutics, Inc.
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics is advancing sevasemten — an oral fast myosin inhibitor with FDA Fast Track designation for Duchenne (February 2024), Orphan Drug Designation, and Rare Pediatric Disease Designation (November 2023) — in a pivotal cohort for Becker muscular dystrophy and multiple Phase 2 trials in Duchenne, plus EDG-7500 (Phase 2, hypertrophic cardiomyopathy) and EDG-15400 (Phase 1 initiated September 2025, targeting heart failure with preserved ejection fraction). The company held $530.1 million in cash and equivalents at December 31, 2025, against an accumulated deficit of $546.4 million and a 2025 net loss of $167.8 million.
Edgewise Therapeutics has not generated any revenue and funds operations through equity offerings — in April 2025 the company closed an underwritten offering of 9,935,419 shares for net proceeds of $187.1 million. The company contracts with third-party manufacturers for clinical supply of sevasemten, EDG-7500, and EDG-15400, creating dependency on those contractors' capacity and quality systems. Sevasemten targets Duchenne and Becker through a mutation-agnostic fast myosin inhibitor mechanism, distinct from the four FDA-approved exon-skipping drugs marketed by Sarepta Therapeutics and Nippon Shinyaku that collectively cover approximately 29% of Duchenne patients. EDG-7500 targets both obstructive and nonobstructive hypertrophic cardiomyopathy, addressing a broader population than the obstructive-only indication covered by current standard of care. Edgewise retains global development and commercialization rights to all programs.
Show full overview
The 10-K states the company is substantially dependent on the success of sevasemten and EDG-7500. The pivotal cohort for Becker is the highest-value near-term binary readout: Becker has no approved therapies on the market, making sevasemten the only drug in late-stage development for that indication. In Duchenne, Sarepta announced in November 2025 that AMONDYS 45 and VYONDYS 53 missed their confirmatory trial primary endpoints, which may affect their accelerated FDA approval status — but sevasemten's own regulatory approval for Duchenne remains contingent on its clinical trials. A failure in either the Becker pivotal cohort or the Duchenne Phase 2 program could substantially harm the company's enterprise value.
See also: Healthcare · Biotechnology
From Edgewise Therapeutics, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated Nov 2, 2026Recent Developments — Edgewise Therapeutics, Inc.
Latest news
- NEWS Edgewise Therapeutics Reports Inducement Grants — fiscal.ai Nov 2, 2026 neutral
- NEWS Analyst Initiates Coverage on Edgewise Therapeutics — fiscal.ai Oct 21, 2026 neutral
- NEWS William Blair Initiates Coverage On Edgewise Therapeutics with Outperform Rating — benzinga Oct 16, 2026 positive
- NEWS Edgewise Therapeutics Doses First Participant In EQUINOX-HFpEF Study Of EDG-15400 To Treat Adults With Symptomatic Heart — benzinga Oct 8, 2026 positive
- NEWS Edgewise Therapeutics Says Preclinical Data Show Hypertrophic Cardiomyopathy Candidate EDG-7500 Improves Cardiac Relaxat — benzinga Sep 22, 2026 positive
Latest item Nov 2, 2026 · Generated 2026-11-04T11:59:35Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinesevasemten and EDG-750010-K Item 1A: 'We are substantially dependent on the success of our lead product candidates, sevasemten and EDG-7500.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $37.68: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 3.45; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $35.04. Score 5.2/10, moderate confidence.
Analyst target: $46.98 (+24.7% upside). Prior stop was $35.04. Stop-loss: $35.04.
Concentration risk — Pipeline: sevasemten and EDG-7500; Quality below floor (1.6 < 4.0).
Edgewise Therapeutics, Inc. trades at a P/E of N/A (forward -20.2). TrendMatrix value score: 7.5/10. Verdict: Sell.
19 analysts rate EWTX, with a consensus score of 4.3/5. 12 analysts publish price targets averaging $54.
What does Edgewise Therapeutics, Inc. do?Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for...
Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for rare muscle diseases, with sevasemten in a pivotal cohort for Becker muscular dystrophy and multiple Phase 2 trials for Duchenne, plus EDG-7500 in Phase 2 for hypertrophic cardiomyopathy. The company has no approved products and no revenue, with a $167.8 million net loss in 2025 and $530.1 million in cash and equivalents at December 31, 2025.